Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Peripheral Blood vs Umbilical Cord Blood Eye Drops in Ocular Surface Disease
NCT07551843Phase 2Completed
- Sponsor
- G. Gennimatas General Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous human platelet lysate, umbilical cord blood platelet lysate and Autologous serum eye drops 20% in dry eye disease (DED) (3 arms), sponsored by G. Gennimatas General Hospital. Primary endpoints: Tear Break-Up Time at 4 weeks, Schirmer test at 4 weeks and 2 more. Started Oct 2023; status: completed.
02
Drugs
autologous human platelet lysateumbilical cord blood platelet lysateAutologous serum eye drops 20%
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07551843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551843.